Mindpeak builds AI-driven digital pathology algorithms that support pathologists in routine diagnostics by automating tissue analysis for faster, more accurate results. The company’s solutions have been deployed for routine clinical diagnostics in both the US and EU and have supported over 30,000 patient diagnoses to date. Mindpeak serves clinical labs and biopharma companies, including strategic partnerships with organizations such as Roche. The firm recently expanded its product portfolio to cover additional organs, biomarkers, and stainings. Positive regulatory developments and growing market adoption have bolstered its position in digital pathology. Mindpeak reports a cash-flow positive core business and plans to accelerate development and commercialisation of its technologies across several geographies. MindPeak develops artificial intelligence software to assist histopathologists in clinical routine cancer diagnostics, focusing on automated detection and quantification of tumor and malignant cells in human tissue. Its first product is a breast-cancer quantification tool designed to identify and quantify tumorous regions and detect breast cancer cells, and the company plans to expand its product portfolio to additional cancer types. MindPeak says its solution improves pathologists' throughput and accuracy by enabling detection and classification of up to ten times more cells in a fraction of the time and can reduce diagnostic costs by up to 90% while improving accuracy. The software is built to work out of the box and be robust against laboratory variations; the company has partnered with research institutes such as Charité Hospital Berlin and clinical labs in Hamburg and Cambridge. Founded in 2018, MindPeak's team includes data scientists from Cambridge, UC Berkeley, Princeton and TU Munich, and co-founders Felix Faber and Dr. Tobias Lang bring entrepreneurship and deep-learning experience. The company is based in Hamburg, Germany.

Total raised

$19M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2024